- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00055549
Dextromethorphan to Treat Patients With Voice Spasms
The Effects of an NMDA-Receptor Antagonist in Idiopathic Voice Disorders
This study will examine how dextromethorphan, a drug that alters reflexes of the larynx (voice box), might change voice symptoms in people with voice disorders due to uncontrolled laryngeal muscle spasms. These include abductor spasmodic dysphonia (breathy voice breaks), adductor spasmodic dysphonia (vowel breaks), muscular tension dysphonia (tight strained voice), and vocal tremor (tremulous voice). Dextromethorphan-one of a group of drugs called NMDA antagonists-has been used for years in over-the-counter cough suppressant medicines. In animal studies, the drug has blocked one of the reflexes in the larynx that may be associated with spasms in the laryngeal muscles. This study will compare the effects of dextromethorphan, lorazepam (a valium-type drug), and a placebo (inactive substance) in patients with the four types of voice disorders described above.
Patients with spasmodic dysphonia, muscular tension dysphonia and vocal tremor may be eligible for this study. Individuals who smoke or use tobacco, who have vocal nodules or polyps, or who have a history of airway obstruction may not participate. Candidates will be screened with a medical history and physical examination, a questionnaire, voice recording (repeating sentences into a microphone), and nasolaryngoscopy (examination of the larynx with a tube advanced through the nose). For the nasolaryngoscopy, the inside of the nose is sprayed with a decongestant (to open the nasal passages) and possibly a local anesthetic. A small, flexible tube called a nasolaryngoscope is passed through the nose to look at the larynx during speech and other tasks, such as singing, whistling and prolonged vowels.
Participants will be admitted to the NIH Clinical Center for each of three visits, which will last from the afternoon of one day to late afternoon of the following day. At each visit, patients will complete a questionnaire, baseline speech recording, and a test for sedation level. They will take three pills-either dextromethorphan, lorazepam, or placebo-one every 6 hours. Vital signs will be checked every 6 hours and the level of sedation during waking hours will be monitored. One to three hours after taking the third pill, speech recording, questionnaire and test of sedation will be repeated to check for possible voice changes. Patients will be given a different pill at each visit.
...
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Studies of spasmodic dysphonia (SD) have increasingly pointed to the possibility of a central sensori-motor control disorder. Sensori-motor processing has been found abnormal in both adductor and abductor spasmodic dysphonia based on reflex conditioning studies. These studies demonstrated an increased frequency of R2 muscle responses during rapid paired presentation of electrical stimuli to the superior laryngeal nerve in spasmodic dysphonia. Thus, uncontrolled R2 responses were hypothesized to be the basis for the uncontrolled muscle bursts in these patients. Selective suppression of late R2 laryngeal adductor responses by N-methyl-D-Aspartate (NMDA) blockade in cats was demonstrated by Ambalavanar et.al. In particular, dextromethorphan reduced the frequency of R2 responses from 95% to 25% (P = 0.015). Dextromethorphan is a widely used antitussive agent that has been in use for over 30 years. In a double-blind randomized crossover design, 3 groups of patients will receive be randomly assigned to one of 6 order cohorts. They will then receive either dextromethorphan at a 8 mg/kg/d dose divided in a Q6 hour dosing schedule with only 3 doses administered PO every 6 hours for 3 dosages, 04 mg/kg/d of lorazepam PO every 6 hours for 3 dosages or a placebo administrated in the same way during Phase A. After a minimum of a 1-week washout interval, the patients will be given either the other medication or placebo during Phase B and then the remaining medication or placebo during Phase C.
Our hypothesis is that dextromethorphan, an NMDA receptor blocker, will reduce voice breaks in spasmodic dysphonia to a greater degree than lorazepam, which has similar sedating side effects, but does not affect NMDA receptors with a different mechanism. On the other hand, patients with other idiopathic voice disorders, muscular tension dysphonia and vocal tremor, are hypothesized not to have a similar benefit from dextromethorphan. During the double-blind randomized cross-over study, three groups will be included, 10 patients with adductor or abductor spasmodic dysphonia, 10 with muscular tension dysphonia and 10 with vocal tremor. The results will determine if dextromethorphan has potential as a treatment option for patients with adductor or abductor SD.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Patients with Spasmodic Dysphonia will meet the following criteria:
- No structural abnormalities affecting the larynx such as vocal fold nodules, polyps, carcinoma, cysts, contact ulcers, inflammation (laryngitis).
- Symptoms of adductor or abductor spasmodic dysphonia present during speech and not apparent at rest,
- Symptoms of adductor or abductor spasmodic dysphonia less evident during whisper, singing or falsetto.
- Symptoms of adductor or abductor spasmodic dysphonia become worse with prolonged speaking, practice or anxiety.
- Reflexive and emotional aspects of voice function are unaffected, such as coughing and laughter or crying.
Patients with Muscular Tension Dysphonia will meet the following criteria:
- Increased phonatory muscle tension in the paralaryngeal and suprahyoid muscles on palpation,
- Constant elevation of the larynx in the neck during speech.
- A consistent hypertonic laryngeal posture for phonation, either an open posterior glottic chink between the arytenoid cartilages on phonation, an anterior-posterior squeeze (pin hole posture) or ventricular hyperadduction.
- A normally appearing larynx.
Patients with vocal tremor will have tremor isolated to the larynx without noticeable tremor of the head and pharynx. Tremor of the vocal folds should be evident during a prolonged vowel and also noticeable in the larynx during connected speech containing vowels.
EXCLUSION CRITERIA:
Subjects in all three groups will be without:
- Cardiac, pulmonary, neurological, psychiatric or speech and hearing problems as determined by medical history and examination by a physician and an EKG. Any patient with a history of airway obstruction will be excluded from the study.
- Reduction in the range of vocal fold movement during non-speech tasks such as whistling suggesting either paralysis or paresis, joint abnormality or neoplasm.
- No smokers or tobacco users will be included in the study.
- Exclude mucosal changes such as vocal nodules or polyps.
- Subjects with a history of a psychiatric disorder, under the care of a psychiatrist, or on medications for treatment of a psychiatric disorder will be excluded from study. Examples of psychiatric disorders to be excluded are: somatoform disorders, conversion disorders, currently under treatment for a major depression, or a history of schizophrenia or a bipolar disorder. However, a history of a previous episode of a minor reactive depression would not exclude a person from participation.
- Subjects taking carbonic anhydrase inhibitors, cimetidine, hydrochlorthiazide, nicotine, quinidine, ranitidine, sodium or calcium bicarbonate and triamterene must either discontinue these medications or be excluded from study.
- Subjects with grade 2 or higher hepatic or renal dysfunction will be excluded from study.
- Pregnant women will be excluded from the study as it is not known if the study drugs are harmful to the fetus. If a woman becomes pregnant during the study, she will be removed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Publications and helpful links
General Publications
- Ambalavanar R, Ludlow CL, Wenthold RJ, Tanaka Y, Damirjian M, Petralia RS. Glutamate receptor subunits in the nucleus of the tractus solitarius and other regions of the medulla oblongata in the cat. J Comp Neurol. 1998 Dec 7;402(1):75-92.
- Ambalavanar R, Purcell L, Miranda M, Evans F, Ludlow CL. Selective suppression of late laryngeal adductor responses by N-methyl-D-aspartate receptor blockade in the cat. J Neurophysiol. 2002 Mar;87(3):1252-62. doi: 10.1152/jn.00595.2001.
- Aminoff MJ, Dedo HH, Izdebski K. Clinical aspects of spasmodic dysphonia. J Neurol Neurosurg Psychiatry. 1978 Apr;41(4):361-5. doi: 10.1136/jnnp.41.4.361.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Neurologic Manifestations
- Otorhinolaryngologic Diseases
- Laryngeal Diseases
- Voice Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Respiratory System Agents
- Antitussive Agents
- Dextromethorphan
- Lorazepam
Other Study ID Numbers
- 030119
- 03-N-0119
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Voice Disorders
-
Universidad Nacional de ColombiaCompleted
-
University of DelawareUmit Dasdogen; Shaheen Awan; Brian Katz; Pasquale BottalicoNot yet recruitingVirtual Reality | Voice and Voice Disorders
-
Hacettepe UniversityCompletedVoice | Voice Disorders in ChildrenTurkey
-
University of UtahNational Institute on Deafness and Other Communication Disorders (NIDCD)SuspendedVoice Disorders | Voice Hoarseness | Voice FatigueUnited States
-
Federal University of Health Science of Porto AlegreUnknown
-
Chulalongkorn UniversityUnknown
-
Nationwide Children's HospitalAgency for Healthcare Research and Quality (AHRQ)Completed
-
Fundacion para la Investigacion Biomedica del Hospital...Instituto de Salud Carlos IIIRecruitingMusic | Cochlear Implant | VoiceSpain
-
Hitit UniversityCompletedIntubation Complication | Voice AlterationTurkey
-
Syracuse UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedEssential Voice Tremor | Voice Tremor | Vocal Tremor | Essential Tremor of VoiceUnited States
Clinical Trials on Dextromethorphan
-
Boehringer IngelheimCompleted
-
PfizerCompletedHealthy VolunteersBelgium
-
National Institute of Neurological Disorders and...CompletedParkinson's Disease | Neurodegenerative DiseaseUnited States
-
National Institute of Dental and Craniofacial Research...CompletedDiabetic Neuropathies | Neuralgia | Herpes ZosterUnited States
-
Hugo W. Moser Research Institute at Kennedy Krieger...The Johns Hopkins Institute for Clinical and Translational Research (ICTR)CompletedRett SyndromeUnited States
-
National Institute on Drug Abuse (NIDA)Unknown
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Fatigue | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
PfizerMedivation, Inc.CompletedAlzheimer Disease | Huntington DiseaseUnited States
-
Profil Institut für Stoffwechselforschung GmbHHeinrich-Heine University, DuesseldorfCompletedType 2 Diabetes MellitusGermany